Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

• Ksenija Nesic,
• Katherine Rybinski,
• Gayanie Ratnayake,
• Gwo‐Yaw Ho,
• Ratana Lim,
• Marc Radke,
• Chloe Neagle,
• Elizabeth M. Swisher,
• Matthew J. Wakefield,
• Holly E. Barker,
• Keiji Furuuchi,
• Clare L. Scott,
• Cassandra J. Vandenberg

Affiliations

Ksenija Nesic

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Katherine Rybinski

Eisai Inc Exton Pennsylvania USA

Gayanie Ratnayake

The Royal Women's Hospital Parkville Victoria Australia

Gwo‐Yaw Ho

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Ratana Lim

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Marc Radke

University of Washington Seattle Washington USA

Chloe Neagle

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Elizabeth M. Swisher

University of Washington Seattle Washington USA

Matthew J. Wakefield

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Holly E. Barker

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Keiji Furuuchi

Eisai Inc Exton Pennsylvania USA

Clare L. Scott

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia

Cassandra J. Vandenberg

Walter and Eliza Hall Institute of Medical Research Parkville Victoria Australia